Malaria
Conditions
Interventions
Treatment group:A naphthoquine-azithromycin compounded formulation
Treatment group:Naphthoquine
Placebo group:Placebo
Sponsors
Yunnan Institute of Parasitic Diseases
Eligibility
Sex/Gender
All
Age
5 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Subjects were residents of malaria-endemic areas; 2. All subjectsor or their Legal guardian voluntarily signed informed consents before the trial; 3. Ranged in age from 5–65 years-of-age male or female; 4. Subjects with no medical history or otherwise physically healthy; 5. With 1 month prior to the screening were not participating in another trial.
Exclusion criteria
Exclusion criteria: (1) In the screening period had malaria symptoms or were positive for Plasmodium parasites according to a blood smear; (2) had a history of malaria in past two weeks; (3) had received antimalarial therapy in the past two weeks; (4) had received malaria prophylaxis in the past three months; (5) had a known or suspected allergy to macrolides, naphthoquine, or other product components; (6) had known or suspected liver and kidney dysfunction; (7) known or suspected poor compliance; (8) were pregnant or lactating women; (9) had another disease(s) that might affect the assessment of therapeutic efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median time and mean time for smear positive;Total Positive rate of blood smear;Positive rate of blood smear; | — |
Countries
China
Contacts
Public ContactHenglin Yang
Yunnan Institute of Parasitic Diseases
Outcome results
None listed